Breaking and Making Tolerance: The PD-1/PD-L1 Axis in Lupus Nephritis

The PD-1/PD-L1 axis is a key immune checkpoint that maintains peripheral tolerance by restraining T-cell activation. In lupus nephritis (LN), this pathway has long been viewed as protective, based on Pdcd1-deficient mice developing lupus-like nephritis and PD-L1 fusion protein efficacy in mouse models. However, recent clinical findings reveal a paradox: PD-1⁺ T cells - especially CD8⁺ and CD4⁺ subsets - are greatly expanded in blood and kidneys of LN patients, correlating with disease activity, proteinuria, and renal decline.

To reconcile the protective and pathogenic roles of PD-1/PD-L1 signaling and propose a unifying "signal balance model" for precision immunomodulation.

These PD-1⁺ cells are not exhausted but exhibit an activated, clonally expanded effector phenotype (granzyme B, perforin, IFN-γ) that drives tissue injury, while PD-1⁺ Tph and Tfh cells promote autoantibody production. The biphasic nature of PD-1/PD-L1 signaling arises from T-cell subset heterogeneity, inflammatory cytokines (IL-12, IFN-α) that override inhibition, costimulatory signals, and reverse signaling through PD-L1 on renal parenchymal cells.

We propose that the net outcome - protection versus pathogenesis - depends on the relative weights of these four determinants, further influenced by genetic background (e.g., PDCD1 polymorphisms). PD-1 agonism (rosnilimab, PD-L1-Fc, nanoparticle delivery) offers promise, but the pathogenic activity of PD-1⁺ effector T cells argues against a uniform approach. Our framework provides a basis for patient stratification, biomarker development, and combination strategies, ultimately guiding a shift from broad immunosuppression to tailored therapy in LN and informing future translational research.